Matinas Biopharma (NYSEAMERICAN:MTNB – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($9.35) earnings per share for the quarter, FiscalAI reports.
Matinas Biopharma Stock Performance
Shares of Matinas Biopharma stock traded up $0.01 on Tuesday, hitting $0.94. 2,708 shares of the company traded hands, compared to its average volume of 128,909. Matinas Biopharma has a 52 week low of $0.81 and a 52 week high of $18.02. The business has a 50-day simple moving average of $2.12 and a 200 day simple moving average of $6.50. The stock has a market capitalization of $921,984.00, a P/E ratio of -0.05 and a beta of 2.24.
About Matinas Biopharma
Matinas BioPharma is a biopharmaceutical company focused on developing medicines using its lipid nanocrystal (LNC) delivery technology. The platform is designed to help deliver drugs that can be difficult to administer or absorb, including through oral formulations. The company’s development programs have included MAT2203, an oral formulation of amphotericin B studied for serious fungal infections, and MAT2501, an oral formulation of amikacin investigated for difficult-to-treat bacterial infections.
Read More
- Five stocks we like better than Matinas Biopharma
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
